Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Risk-adapted therapy of AML

Christoph Röllig • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Christoph Röllig, MD, MSc, of Dresden University of Technology, Dresden, Germany, discusses the risk-adapted therapy of acute myeloid leukemia (AML), highlighting the rationale behind combination therapy in specific subgroups. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Christoph Röllig

2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023
1:45
HAM-Ven as salvage treatment for R/R AML: results from the SAL-RELAX trial
Christoph Röllig • 11 Dec 2023
2:26
Improving long-term outcomes with intensive chemotherapy in AML: looking to the future
Christoph Röllig • 11 Dec 2023
2:05
Results from the Phase I SAL-RELAX trial: venetoclax plus cytarabine and mitoxantrone in R/R AML
Christoph Röllig • 10 Dec 2022

Related Videos

1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals